Jacobs Celine, Lapeire Lore
Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
Diagnostics (Basel). 2021 Mar 14;11(3):512. doi: 10.3390/diagnostics11030512.
Soft tissue sarcomas are a group of rare mesenchymal tumors with more than 70 subtypes described. Treatment of these subtypes in an advanced setting is mainly according to a one-size-fits-all strategy indicating a high unmet need of new and more targeted therapeutic options in order to optimize survival. The introduction of advanced molecular techniques in cancer has led to better diagnostics and identification of new therapeutic targets, leading to more personalized treatment and improved prognosis for several cancer types. In sarcoma, a likewise evolution is seen, albeit at a slower pace. This manuscript describes how in the past years advanced molecular profiling in soft tissue sarcomas was able to identify specific and often pathognomonic aberrations, deferring standard sarcoma treatment in favor of more targeted treatment from an oncologist's point of view.
软组织肉瘤是一组罕见的间充质肿瘤，已描述的亚型超过70种。在晚期情况下对这些亚型的治疗主要依据一刀切的策略，这表明迫切需要新的、更具针对性的治疗选择以优化生存率。癌症中先进分子技术的引入带来了更好的诊断方法以及新治疗靶点的识别，从而实现了更个性化的治疗并改善了多种癌症类型的预后。在肉瘤中也出现了同样的进展，尽管速度较慢。本文描述了在过去几年中软组织肉瘤的先进分子谱分析如何能够识别特定且往往具有诊断意义的畸变，从肿瘤学家的角度来看，这使得标准肉瘤治疗让位于更具针对性的治疗。
